CDMO: Avid Bioservices, Inc. Stock

by  •  • Comments Off on CDMO: Avid Bioservices, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 783.46
Enterprise Value ($M) 903.94
Book Value ($M) 58.64
Book Value / Share 0.92
Price / Book 13.36
NCAV ($M) -172.39
NCAV / Share -2.70
Price / NCAV -4.54

Profitability (mra)
Return on Invested Capital (ROIC) -0.54
Return on Assets (ROA) -0.32
Return on Equity (ROE) -0.78

Liquidity (mrq)
Quick Ratio 1.05
Current Ratio 1.46

Balance Sheet (mrq) ($M)
Current Assets 103.62
Assets 334.64
Liabilities 276.01
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Point72 Asset Management, L.P. 8.30 63.75
11-12 13G/A Integrated Core Strategies (us) Llc 1.40 -79.22
10-17 13G/A State Street Corp 4.70 -37.24
02-14 13G T. Rowe Price Investment Management, Inc. 6.90 20.64
02-13 13G/A Vanguard Group Inc 5.72 -16.82
01-26 13G/A AltraVue Capital, LLC 4.70 -9.95
01-08 13G/A BlackRock, Inc. 8.40 -46.75

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-09-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-07-02 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-04-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 ☐ TRANSITION
2024-04-24 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)
2024-04-24 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 ☐ TRANSITION REPORT PURSUANT T
2024-04-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 ☐ TRANSITI
2023-12-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2023 ☐ TRANSITION REPORT PURSUANT T

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-22 212,594 2,095,357 10.15
2024-11-21 87,790 2,179,844 4.03
2024-11-20 126,040 1,030,824 12.23
2024-11-19 202,002 1,552,591 13.01
2024-11-18 137,712 1,168,816 11.78

(click for more detail)

Similar Companies
CARA – Cara Therapeutics, Inc. CASI – CASI Pharmaceuticals, Inc.
CDIO – Cardio Diagnostics Holdings, Inc. CDTX – Cidara Therapeutics, Inc.
CDXC – ChromaDex Corporation


Financial data and stock pages provided by
Fintel.io